Abstract: SA-PO835
Kidney Prognostic Value of Serum Monoclonal Immunoglobulin in Nonautoimmune Diseases Related to Cryoglobulinemic Glomerulonephritis
Session Information
- C3G, TMA, MGRS, Amyloidosis, and More
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Ma, Lei, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Liang, Dandan, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Xia, Yuanyuan, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Xu, Feng, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Liang, Shaoshan, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Chen, Dacheng, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Yao, Xinchen, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Yang, Fan, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Zhu, Xiaodong, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
- Zeng, Caihong, National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, NanJing, China
Background
To explore the clinicopathological features and renal outcome in patients with cryoglobulinemic glomerulonephritis (Cryo-GN) without evidence of autoimmunity disorders.
Methods
Sixty-nine patients with Cryo-GN from a single center were recruited in this retrospective study. Their clinical, pathologic, and follow-up data were collected and analyzed. According to whether the serum monoclonal immunoglobulin (MIg) and HBV-DNA/HBV markers or HCV-RNA/anti-HCV antibodies were positive or not, they were classified into four groups: positive serum MIg only (MIg group), positive HBV-DNA/HBV markers or HCV-RNA/anti-HCV antibodies (HBV/HCV) only (HBV/HCV group), positive serum MIg and HBV/HCV (MIg+HBV/HCV group), and all MIg/HBV/HCV negative group.
Results
The male-to-female ratio was 1.38:1 with a mean age of 50.4±14.7 years in the patient cohort. Hypertension was presented in 59.4% of cases, anemia in 73.9%, renal insufficiency in 58.0%, nephrotic proteinuria in 44.9% and microscopic hematuria in 94.2%. The MIg group had significantly lower eGFR levels, higher cryoglobulin levels, and higher rates of abnormal serum-free light chain ratios than the MIg/HBV/HCV negative group. The most common histological pattern of Cryo-GN was membranoproliferative glomerulonephritis (MPGN), and the MIg group had significantly higher scores of the severity of intracapillary cryo-Plugs than the MIg+HBV/HCV group and the MIg/HBV/HCV negative group. Sixty-three patients had a median follow-up of 31.2 months, and 25.4% of them progressed to end-stage renal disease (ESRD). The renal survival was inferior for MIg group than for HBV/HCV group. Multivariate analysis showed that serum MIg and the severity of intracapillary cryo-plugs were independent prognostic factors.
Conclusion
Regardless of the presence of HBV/HCV infection, non-autoimmune diseases related Cryo-GN patients with serum MIg had worse renal function and renal survival. Serum MIg and severity of intracapillary cryo-Plugs were independent risk factors for renal survival in Cryo-GN patients without autoimmune diseases.
Funding
- Government Support – Non-U.S.